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Abstract
Background: Our research compared whole pelvic (WP) and prostate-only (PO) 3-dimensional conformal
radiotherapy (3DCRT) techniques in terms of the incidence and evolution of acute and late toxicity of the rectum
and urinary bladder, and identified the PTV-parameters influencing these damages and changes in antitumor
immune response.
Methods: We analyzed 197 prostate cancer patients undergoing 3DCRT for gastrointestinal (GI) and genitourinary
(GU) toxicities, and conducted a pilot immunological study including flow cytometry and an NK cell cytotoxicity
assay. Acute and late toxicities were recorded according to the RTOG and the LENT-SOMA scales, respectively.
Univariate and multivariate analyses were conducted for factors associated with toxicity.
Results: In the WP group, an increase of acute rectal toxicity was observed. A higher incidence of late GI/GU
toxicity appeared in the PO group. Only 18 patients (WP-7.76% and PO-11.11%) suffered severe late GI toxicity, and
26 patients (WP-11.21% and PO-16.05%) severe late GU toxicity. In the majority of acute toxicity suffering patients,
the diminution of late GI/GU toxicity to grade 1 or to no toxicity after radiotherapy was observed. The 3DCRT
technique itself, patient age, T stage of TNM classification, surgical intervention, and some dose-volume parameters
emerged as important factors in the probability of developing acute and late GI/GU toxicity. The proportion and
differentiation of NK cells positively correlated during 3DCRT and negatively so after its completion with dose-
volumes of the rectum and urinary bladder. T and NKT cells were down-regulated throughout the whole period.
We found a negative correlation between leukocyte numbers and bone marrow irradiated by 44-54 Gy and a
positive one for NK cell proportion and doses of 5-25 Gy. The acute GU, late GU, and GI toxicities up-regulated the
T cell (CTL) numbers and NK cytotoxicity.
Conclusion: Our study demonstrates the association of acute and late damage of the urinary bladder and rectum,
with clinical and treatment related factors. The 3DCRT itself does not induce the late GI or GU toxicity and rather
reduces the risk of transition from acute to late toxicity. We have described for the first time the correlation
between organs at risk, dose-volume parameters, and the immunological profile.
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Quality of life is becoming one of the most significant
issues in treatment decision-making, in general, and
more so in prostate cancer [1]. Thus late rectal and
urinary damage became a major concern in prostate
cancer; and many studies have been dedicated to the
search for correlations between dose-volume, treatment-
related factors, and late GI and GU toxicities [2-7].
Three-dimensional conformal radiotherapy (3DCRT)
represents one of the standard treatments of prostate
cancer allowing the delivery of highly “conformed”
(focused) radiation to the cancer cells, while significantly
reducing the amount of radiation received by surround-
ing healthy tissue. 3DCRT should increase the rate of
tumor control, while also decreasing side effects. In
spite of this focus, a higher dose to the prostate implies
that the surrounding organs at risk (OARs) may also
receive higher doses.
In addition, local radiation therapy (RT) alters the bal-
ance of circulating immune cells by the depletion of radio-
sensitive cell subsets [8]. Recently, radiation-induced
functional changes in immune cells raised interest, sug-
gesting the possible use of radiation as an antitumor
immune response enhancer. Irradiation can induce leuko-
penia due to apoptosis of various leukocyte subpopula-
tions. The acute exposure to low- and high-dose
irradiation in mouse models changes the quantitative and
functional parameters of immune cells, due to different
sensitivity of splenocyte subsets to radiation doses [9].
Similar effect was described in vitro for cervical cancer
patients [10]. Tabi et al. reported a prevalent loss of naive
and early memory cells vs. more differentiated T cells in
peripheral blood of patients during RT to the pelvis [11].
The release of the heat shock protein 72 (HSP72) during
RT increased the cytotoxic CTL and NK cells [12]. Some
pathological changes can be caused by the apoptosis of
bone marrow (BM) stem cells and BM stromal damage
[13]. Radiation-induced BM injury depends on both the
radiation dose and the volume of BM irradiated [14].
We performed a prospective 4-year study, enrolling
prostate cancer patients to elucidate whether the risk
level of acute and particularly late rectal and urinary
toxicities caused by 3DCRT techniques (whole pelvic
(WP) and prostate-only (PO)), are at an acceptable level.
This study reports our 42-month follow-up results, and
evaluates the relationships between pretreatment, acute
and late rectal and urinary syndromes and tumor-,
patient- and treatment-related factors. In the last 3 years
of the study, we investigated the influence of 3DCRT
techniques, as well as the GI and GU toxicity on
selected patient immune parameters, with special regard
to the cells involved in antitumor immunity (natural
killer-NK, NKT, and T).
Methods
Patients and clinical protocol
Data for the study were collected from 245 consecutive
patients with Stage T1 to T3 clinically localized prostate
adenocarcinoma, treated with 3DCRT (2004-2009) at
the Department of Radiotherapy and Oncology, Motol
University Hospital, Prague, Czech Republic. 48 patients
with follow-up shorter than 24 months were excluded
from the study. The study population thus consisted of
197 patients. Patients according to their health and
lymph nodal status (classified by Prostate cancer staging
nomograms-Partin tables) [15] were divided into two
groups: those who underwent whole pelvic (WP) radio-
therapy-irradiation of prostate, seminal vesicles, and
lymph nodes followed by a prostate boost (116 patients,
59%); and prostate-only (PO) radiotherapy-irradiation of
prostate and seminal vesicles (81 patients, 41%). Follow-
up evaluations after treatment were performed at 3 to 6
month intervals. The median follow-up was 42 months,
ranging from 24 to 55 months. Main patient characteris-
tics and main disorders are summarized in Table 1.
Acute and late GI and GU toxicities were studied in
order to identify the treatment-related, clinical and
patient characteristics that correlated with the severity
of complications and disorders. Acute reactions included
those arising during treatment or within 90 days after
RT completion. Late complications were defined as
those developing more than 90 days after the last treat-
ment. Acute and late toxicities were scored according to
RTOG and LENT-SOMA morbidity scale (grades 1-5).
Into the category of low toxicities were encompassed
the patients without the need of pharmacological inter-
vention (grade 1), while the serious toxicity (grade ≥ 2)
was under medication. In 37 cases (WP: n = 16; PO: n
= 21) the immune response before treatment, during
3DCRT (day 14), and 15-20 days after treatment com-
pletion was evaluated. The protocol was approved by
the local board ethics committee; and written informed
consent was obtained from all patients.
Irradiation technique, target volume and critical normal
structure definition
Treatment planning and irradiation were performed
with the patients in supine position (using knee and
ankle supports) with an emptied rectum and “comforta-
bly full” bladder filling. 3D conformal treatment plan-
ning based on CT images with 5 mm thickness,
involved delineation of CTVs, PTVs and organs at risk,
a c c o r d i n gt oI C R U5 0a n d6 2r e c o m m e n d a t i o n s .T h e
plans, using MLC to shape beams, were calculated on
Eclipse treatment planning system. Box technique or
four wedged field technique (two lateral and two oblique
fields at angles of 90°, 270°, 30° and 330°) was used. The
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Page 2 of 13dose was normalized to the ICRU reference point,
located in the central part of the PTV or near the cen-
tral axis of the beam intersection, according to ICRU
50. Dose homogeneity was between 95% and 107% of
the ICRU reference dose. Dose-volume histograms were
used for evaluation of doses to target volumes and
organs at risk. DRRs were generated for all treatment
beams and for two extra setup beams from the antero-
posterior (AP) and the lateral directions (LAT).
Before the radiotherapy, the treatment plans were
simulated on a conventional simulator (Ximatron and
Acuity
®, Varian Medical Systems). The isocenter was
marked on the patient’s skin. Patients were irradiated on
a Clinac 2100 C/D (Varian) equipped with Millenium
MLC-120 with beams of 18 MV or 6 MV. The dose was
delivered in daily fractions of 1.8 Gy to the pelvis and of
2 Gy to the prostate and seminal vesicles, in given per-
iod five sessions per week. In the treatment room, the
patients were aligned on a carbon-fiber couch panel
within their immobilization device using the skin marks.
Before the therapy, patient set-up was checked using
electronic portal imaging (PortalVision PV-aS500
®).
Simulator images of setup fields were used as reference
images for matching with portal images. Planning target
volume (PTV) of the prostate (PTV3) was the entire
organ (clinical target volume of prostate-CTV3), and
PTV2 was the entire prostate and seminal vesicles
(CTV2). Both PTVs were enlarged by 1.5 cm margin,
except for the prostate-rectum interface where a 1 cm
margin was again used to decrease the risk of rectal
toxicity. PTV1 in the WP Group was only the CTV of
lymph nodes (LNs). LNs were defined according to
RTOG recommendations (treatment of only subaortic
presacral LNs, contours of common iliac vessels starting
at the L5/S1 interspace, external iliac contours stopping
at the top of femoral heads, and contours of obturator
LNs stopping at the top of the symphysis pubis) plus a
1 cm margin.
Patients from the PO group received a dose of 60 Gy
in 30 fractions to the PTV2. Then the PTV3 received
the prescribed dose of 10-18 Gy in 5-9 fractions.
Patients from the WP group received a dose of 45 Gy in
2 5f r a c t i o n st ot h eP T V 1 ,t h e nad o s eo f2 0G yi n1 0
fractions to the PTV2. Finally the PTV3 received the
prescribed dose 6-10 Gy in 3-5f r a c t i o n s .D o s ev o l u m e
histograms (DVH) were generated for all PTVs and
OARs. The OARs included the bladder, rectum, bone
marrow, and femoral head.
Pelvic bone marrow definition
For each patient, the pelvic bone marrow (PBM) volume
was first defined according to the method described by
Mell et al. [16]. The external contour of the PBM was
delineated on the planning CT using bone windows.
Three sub sites were defined: 1) iliac BM (IBM), extend-
ing from the iliac crests to the superior border of the
femoral head; 2) lower pelvis (LP), consisting of the
pubes, ischia, acetabula, and proximal femora, extending
from the superior border of the femoral heads to the
inferior border of the ischial tuberosities; and 3) lumbo-
sacral spine (LS), extending from the superior border of
Table 1 Patient characteristics
Characteristics WP (n = 116) PO (n = 81)
Age
Median 73 74
Range 57-100 57-92
Mean ± SD 72.93 ± 8.55 74.88 ± 7.79
TNM Stage
T0 1 (0.86%) -
T1 6 (5.17%) 22 (27.16%)
T2 34 (29.31%) 30 (37.04%)
T3 62 (53.44%) 15 (18.52%)
T4 4 (3.45%) 1 (1.24%)
Metastases 2 (1.72%) -
Gleason score
Median 7 5
Range 2-9 3-10
Initial PSA [ng/mL]
Median 19 10
Range 2-133 1-97
Mean ± SD 31.00 ± 8.67 12.46 ± 2.34
ADT 93 (80.07%) 33 (40.74%)
Previous surgery
RP 23 (19.83%) 22 (27.16%)
TURP 7 (6.03%) 5 (6.17%)
Therapy duration (m)
Median 57 54
Range 33-81 22-80
Mean ± SD 57.50 ± 5.56 54.04 ± 7.03
Recurrence Risk*
Low 1 (0.86%) 19 (23.46%)
Intermediate 20 (17.24%) 38 (46.91%)
High 94 (81.03%) 23 (28.40%)
Prescription dose (Gy)
≤ 71 60 (51.72%) 6 (7.41%)
72, 73 53 (45.69%) 72 (88.89%)
≥ 74 3 (2.59%) 3 (3.70%)
Disorders
Without complications 49 (42.24%) 37 (45.86%)
Cystoureteritis 16 (13.79%) 15 (18.52%)
Cystoureteritis + diarrhea 15 (12.93%) 1 (1.23%)
Proctocolitis + diarrhea 28 (24.14%) 14 (17.28%)
Unknown 8 (6.69%) 14 (17.28%)
*Recurrence risk was determined according to Canadian Consensus (Lukka
2002): low risk (T1-2a, Gleason ≤ 6, PSA < 10 ng/mL), intermediate risk (T2b-
2c, Gleason = 7, PSA 10-20 ng/mL), high risk (T3-4, Gleason ≥ 8, PSA > 20 ng/
mL)
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Page 3 of 13the L5 vertebral body to the coccyx, but not extending
below the superior border of the femoral head. To find
the association of local radiation doses and changes in
the number of leukocytes among patients with different
body sizes, the percentage of BM irradiated volume at
different doses was used as a first approximation.
Cell separation for immunological evaluations
Citrated blood samples from patients were separated by
Ficoll-Hypaque 1,077 (Sigma-Aldrich, St. Louis, MO,
USA) density centrifugation for 40 min to obtain the
peripheral blood mononuclear cell (PBMC) fraction.
Flow cytometry
The fluorochrome-conjugated antibodies CD3-Pacific
Blue (UCHT1), CD4-APC-Alexa Fluor 750 (S3.5), CD8-
Pacific Orange (3B5) CD19-Pacific Blue (HD37), CD20-
PE-Cy7 (2H7), CD38-PerCP-Cy5.5 (HIT2), and CD56-
APC (MEM-188), were obtained from Dako (Glostrup,
Denmark), Exbio (Prague, Czech Republic), BD Bios-
ciences (Franklin Lakes, NJ, USA), and e-Bioscience
(San Diego, CA, USA). PBMCs (5 × 10
5 cells/well) were
stained with the antibody mixture for 30 min on ice,
washed, and measured with a Becton Dickinson LSRII
instrument (BD Biosciences). We included single-stain
controls for further offline compensation. Measurement
and subsequent analysis was performed using FACSDiva
(BD Biosciences) and TreeStar FlowJo 8 (Ashland, OR,
USA) software, respectively.
NK cell-mediated cytotoxicity
The standard
51Cr-release assay was performed with
PBMCs from patients as effectors and the NK cell-sensi-
tive K562 erythroleukemia cell line as targets. PBMC
(1.6 × 10
5 cells/well) were incubated with 10
4
Na2
51CrO4-labeled target cells in round-bottomed 96-
well microtitre plates (NUNC) at 37°C, in a humidified
atmosphere containing 5% CO2. NK cell activity was
evaluated after 4 hr of incubation, and calculated as
described previously [17].
Statistical analysis
We investigated all GI and GU toxicities (late and acute)
separately. There were only 3 cases of grade 3 acute GI
toxicity, only 5 cases of grade 3 acute GU toxicity, and
none of grade 4 or 5. Similar observation was made for
late GI toxicity (only 5 cases of grade 3, 1 of grade 4, and
no instances of grade 5) and for late GU toxicity (only 13
patients of grade 3 and none of grade 4 or 5). As a conse-
quence, we grouped the toxicity levels of all diagnosed
toxicities (acute GI, acute GU, late GI, and late GU) in
two categories and analyzed the binary response. The
grouping of responses considered was: high toxicity
(grade 2-3) vs. low or no toxicity (grades 1 or 0).
The grouped data were analyzed using multivariate
logistic regression models. The list of predictive factors
was the same for acute and late toxicities; except for the
addition of acute toxicity, as the next predictive factor
of late OAR damage. The patient-, tumor-, and treat-
ment-related factors were as follows: 3DCRT technique
used (WP vs. PO); volumes of rectum and urinary blad-
der; minimum, maximum, and mean dose received by
the rectum and urinary bladder (Dmin,D max,D mean);
percentage of rectum and urinary bladder volume
receiving 40 Gy, 50 Gy, 60 Gy, and 70 Gy, respectively;
patient age; stage T of TNM classification; initial PSA;
Gleason score; androgen deprivation therapy (ADT)
added to RT (yes/no); surgical intervention (None/
Transurethral resection/Radical prostatectomy) of the
prostate (NONE/TURP/RP); occurrence of hemorrhoids
(yes/no); and duration of RT (weeks). A Pearson’s c
2
test or, in the case of small sample size, Fisher’se x a c t
test was used to examine whether there was a statisti-
cally significant difference in the occurrence and evolu-
tion of acute and particularly late GU and GI toxicity
between the two observed 3DCRT techniques.
To evaluate the association of immune response and
toxicity level, the patients were divided in the group T
(patients with any toxicity level-grades 1-3) and group 0,
those with no toxicity (grade 0). To compare the
immune parameters between these groups of patients
the t-test was performed. To find the relationship
between immune response in prostate cancer patients
and treatment related factors, Pearson’s correlation coef-
ficients were calculated.
For statistical analysis Statsoft’s STATISTICA version
9 and SPSS Statistics version 18 were used. All tests
were considered to be statistically significant at the level
of p < 0.05. The required sample size for all performed
statistical tests was calculated using IBM SPSS Sample-
Power software version 3.
Results
Logistic regression models for GI and GU toxicities
Four logistic regression models for acute GI, acute GU,
late GI, and late GU toxicity were created. All models
were statistically significant and adequately interpolated
the data; however in both models for late toxicities, GI
and GU, a large disparity between the number of
patients in groups with high toxicity vs. low or no toxi-
city was observed. The classification ability of all four
models was very good-80.0% for acute GI toxicity, 78.9%
for acute GU toxicity, 76.3% for late GI toxicity, and
76.0% for late GU toxicity. The area under the ROC
curve (AUC) which determines the discrimination
power of the logistic model reached the following
values: 0.836 for acute GI toxicity-discrimination quality
according to Tape [18], “Good"; 0.810 for acute GU
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Page 4 of 13toxicity-"Good"; 0.784 for late GI-"Fair"; and 0.761 for
late GU toxicity-"Fair”.
The significance level and odds ratio for statistically
significant regression coefficients are summarized in
Table 2 for acute and late GI and GU toxicity. Acute GI
and GU toxicities were significantly dependent on
patients’ increasing age, and the chance of developing
high toxicity levels greaten. For late GI and GU toxici-
ties, the larger irradiated volume of OARs (rectum and
urinary bladder) enhanced the chance of high-level toxi-
city occurrence. Other important predictors of acute GI
toxicity were the percentage of rectum volume receiving
70 Gy (the higher the percentage of rectum, the higher
the chance of high level toxicity) and the 3DCRT tech-
nique used, where the high-level toxicity developed
when the WP technique was used (26.16 times greater
than in the case of the PO technique). The higher T
stage of TNM classification and the acute GI toxicity
significantly increased the probability of late GI toxicity
occurrence. The results pointed to the significant asso-
ciation of acute GU toxicity and the percentage of the
urinary bladder receiving 50 Gy, and the association of
late GU toxicity with the percentage of the urinary blad-
der receiving 40 Gy. Both types of urinary toxicities
(acute and late) were augmented by radical prostatect-
omy prior to radiotherapy (NONE vs. RP) that increased
the occurrence of high-level toxicity for acute and late
GU toxicity 7.35 times (OR = 0.136) and 11.15 times
(OR = 0.090), respectively. Another important statisti-
cally significant predictor found for late GU toxicity was
the PO type of 3DCRT that evoked the development of
high-level toxicity 1.72 times more (OR = 0.580) in
comparison with WP technique.
GI and GU toxicity evolution after WP and PO 3DCRT
techniques
The used 3DCRT technique was proven as an important
factor influencing the development of GI and GU toxi-
city. Consequently, we analyzed the occurrence and evo-
lution of late GI and GU toxicity from pretreatment
symptoms through acute GI and GU toxicity in each
group of patients separately. The proportion of patients
suffering pretreatment GU, as well as GI pathologies,
was comparable in the groups undergoing either the
WP or PO 3DCRT therapy. The proportion of GU toxi-
city did not change significantly between the WP and
PO techniques in all appearing grades (0-3). The results
of toxicity dynamics are summarized in Table 3. The
values of the last late GI and GU toxicity observed in
patients during their last inspection are shown.
In the cohort of patients included in the WP group,
pretreatment GI toxicity of grade 2 was found in the
history of 2 patients (1.72%), and only 1 patient (0.86%)
showed grade 3. During treatment or within the first 90
days after treatment, acute grade 2 GI toxicity occurred
in 65 (56.03%) and grade 3 GI toxicity in 3 patients
( 2 . 5 9 % ) .T h es e v e r el a t eG It o x i c i t yo fg r a d e2o c c u r r e d
in 5 (4.31%), grade 3 in 3 patients (2.59%), and grade 4
in 1 patient (0.86%). There were no late grade 5 GI toxi-
city-suffering patients in this group. Pretreatment GU
damage of grade 2 was found in the history of 4 patients
(3.44%) and grade 3 in the history of 2 patients (1.72%).
WP 3DCRT evoked acute grade 2 GU toxicity in 30
(37.04%) and acute grade 3 GU toxicity in 4 patients
(3.45%). Severe late GU toxicity of grade 2 occurred in 8
patients (5.76%) and grade 3 in 6 patients (7.41%).
There were no late grade 4 or 5 GU toxicities observed.
Table 2 Logistic regression models for acute and late GI and GU toxicities.
Acute GI toxicity Late GI toxicity
Variable OR 95% CI p Variable OR 95% CI p
Age 1.097 1.03-1.17 0.006 Volume of rectum 1.028 1.00-1.06 0.036
Percentage of rectum receiving
70 Gy
1.134 1.03-1.25 0.009 T stage of TNM classification 4.630 1.09-20.00 0.037
3DCRT technique
WP vs PO
26.163 5.10 -134.2 0.000 Acute GI
Low vs High
0.115 0.01-0.92 0.042
Acute GU toxicity Late GU toxicity
Variable OR 95% CI p Variable OR 95% CI p
Age 1.108* 1.02-1.20 0.015 Volume of urinary bladder 1.016 1.00-1.03 0.018
Percentage of urinary bladder receiving
50 Gy
1.127 1.01-1.25 0.026 Percentage of urinary bladder receiving
40 Gy
1.144 1.00-1.30 0.045
Surgical intervention
None vs RP
0.161 0.04-0.68 0.013 Surgical intervention
None vs RP
0.089 0.01-0.85 0.035
3DCRT technique
WP vs PO
0.580 0.10-1.74 0.029
Odds ratios (OR), 95% Confidence Intervals (CI) and significance levels (p) of Wald chi-square statistic of patient-, tumor-, and treatment-related factors that meet
statistical significance are presented
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Page 5 of 13Table 3 Scoring of GI and GU disorders for WP and PO 3DCRT techniques.
Incidence and development of acute GI/GU toxicity from pretreatment symptoms
Acute GI toxicity Acute GU toxicity
WP PO WP PO
Pretreatment
Symptoms
Acute toxicity n % n % n % n %
0 ® 0 33 28.45% 40 49.38% 43 37.07% 36 44.44%
0 ® 1 14 12.07% 17 20.99% 18 15.52% 12 14.81%
0 ® 2 58 50.00% 20 24.69% 25 21.55% 17 20.99%
0 ® 3 1 0.86% 1 0.86%
1 ® 0 1 1.23% 13 11.21% 7 8.64%
1 ® 1 2 2.47% 6 5.17% 3 3.70%
1 ® 2 5 4.31% 1 1.23% 4 3.45% 3 3.70%
1 ® 3 2 1.72%
2 ® 0 1 0.86% 1 0.86% 1 1.23%
2 ® 1 1 1.23%
2 ® 2 1 0.86% 1 0.86%
2 ® 3 2 1.72% 1 1.23%
3 ® 0 1 0.86%
3 ® 1
3 ® 2 1 0.72%
3 ® 3 1 0.86%
Development of late GI/GU toxicity from acute GI/GU toxicity
GI toxicity GU toxicity
WP PO WP PO
Acute toxicity Late toxicity n % n % n % n %
0 ® 0 29 25.00% 34 41.98% 41 35.34% 31 38.27%
0 ® 1 5 4.31% 5 6.17% 13 11.21% 8 9.88%
0 ® 2 2 2.47% 1 0.86% 3 3.70%
0 ® 3 1 0.86% 3 2.59% 2 2.47%
1 ® 0 10 8.62% 11 13.58% 17 14.66% 9 11.11%
1 ® 1 4 3.45% 7 8.64% 4 3.45% 2 2.47%
1 ® 2 1 0.86% 2 2.47%
1 ® 3 1 1.23% 2 1.72% 3 3.70%
2 ® 0 47 40.52% 9 11.11% 18 15.52% 10 12.35%
2 ® 1 9 7.76% 6 7.41% 8 6.90% 8 9.88%
2 ® 2 5 4.31% 5 6.17% 3 2.59% 2 2.47%
2 ® 3 2 1.72% 1 1.23% 1 0.86%
2 ® 4 1 0.86%
3 ® 0 2 1.72%
3 ® 1 1 0.86% 2 1.72%
3 ® 2 1 0.86%
3 ® 3 1 0.86% 1 1.23%
Summary of last late GI/GU toxicities dynamics
WP PO
Last late GI toxicity n%n%
Patients without toxicity 29 25.00% 34 41.98%
Decrease of toxicity (G1,2,3®G0) 59 50.86% 20 24.69%
Patients with moderate toxicity-G1
Development G0 ® G1 5 4.31% 5 6.17%
Unchanged grade of toxicity G1 4 3.45% 7 8.64%
Decrease of toxicity from G2, 3® G1 10 8.62% 6 7.41%
Patients with high level toxicity G2, 3, 4 9 7.76% 9 11.11%
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3 or 4 pretreatment GI disorders. During RT or within
the first 90 days after PO 3DCRT, acute grade 2 GI
toxicity occurred in 21 cases (25.93%), and there were
no patients with grade 3 or 4 GI toxicity. 7 patients
(8.64%) suffered severe late grade 2 GI toxicity, and 1
patient (1.23%) grade 3. Prior to radiotherapy, 3 patients
(3.77%) had grade 2 toxicity, and none had grade 3 GU
toxicity. Acute grade 2 GU toxicity developed in 20
(24.69%) and grade 3 in 1 (1.23%) patients. Late grade 2
GU toxicity occurred in 7 (8.64%) and grade 3 in 6
(7.41%) patients. None of the patients in the cohort had
grade 4 of GU toxicity. Figure 1 summarizes the propor-
tion of evolution of GI (Figure 1A) and GU (Figure 1B)
toxicity events from pretreatment through acute to late
damage, for both the WP and PO patient groups. The
only disparity between the two 3DCRT techniques was
found in the case of development of acute GI toxicity,
where a large increase of high level toxicity grades ≥ 2
was observed in the WP group compared to the PO
group. On the other hand, results from Table 3 illustrate
the diminution of toxicity from grades 1-3 to no toxicity
(grade 0), more prominent in the WP group relative to
the PO group. The Pearson’s c
2 test was performed to
determine the statistical significant difference between
the WP and PO 3DCRT techniques, which was observed
only in the occurrence of acute GI toxicity (p = 0.0001).
Correlation between the 3DCRT parameters, GI/GU
toxicity and immune response
We screened the immunological parameters, number of
leukocytes, distribution of lymphocyte populations (T, B,
NK, and NKT cells) and their subsets in the peripheral
blood of patients before, throughout and after the finish-
ing of 3DCRT, and correlated them to dose volume
parameters, as well as to the volume of irradiated bone
marrow.
The relationship of the applied dose and the percen-
tage of volume of bone marrow irradiated are presented
in Figure 2. The highest correlation occurred at a dose
of 46 Gy, as depicted in Figure 3. We found that the
bone marrow irradiation had a significant negative
association with the number of leukocytes, but did not
influence the proportion of NK cells during the irradia-
tion in doses ranging from 44 Gy to 54 Gy (Table 4).
Doses lower than 44 Gy and higher than 54 Gy, did not
exhibit statistically significant correlations with leuko-
cyte number. In the scope of PBM irradiation, we found
a positive correlation between low doses (1-43Gy) and
100%
80%
60%
40%
20%
0%
WP PO
G0 G1 G2 G3 G4
WP PO WP PO
Pretreatment Acute Late
Evolution of GI damage from preatrement through acute to late stages
Evolution of GU damage from pretreatment through acute to late stages
100%
80%
60%
40%
20%
0%
WP PO
G0 G1 G2 G3
WP PO WP PO
Pretreatment Acute Late
B
A
Figure 1 Summary of GI and GU symptoms scoring before and
after 3DCRT. Comparison of GI (A) and GU (B) toxicity between the
PO (n = 106) and the WP (n = 139) patient groups. Patients were
scored according to the modification of RTOG morbidity scale.
Percentage of occurrence of grades G0, G1, G2, and G3 of
pretreatment pathology, acute, and late GU and GI toxicities are
demonstrated.
Table 3 Scoring of GI and GU disorders for WP and PO 3DCRT techniques. (Continued)
WP PO
Last late GU toxicity n%n%
Patients without toxicity 41 35.34% 31 38.27%
Decrease of toxicity (G1,2,3 ® G0) 35 30.17% 19 23.46%
Patients with moderate toxicity-G1
Development G0 ® G1 13 11.21% 8 9.88%
Unchanged grade of toxicity G1 4 3.45% 2 2.47%
Decrease of toxicity from G2, 3®G1 10 8.62% 8 9.88%
Patients with high level toxicity G2, 3, 4 13 11.21% 13 16.05%
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Page 7 of 13NK cell numbers during RT (Table 4). Blood samples of
patients receiving 34-35 Gy to the bone marrow demon-
strated significantly increased proportion of NK (p =
0,002), NKT (p = 0,005) and cytotoxic T cells (p =
0,018) after the end of therapy. Moreover, T lymphocyte
proportions in the patient’s blood correlated positively
with the higher doses (47-62 Gy) of irradiated PBM.
Increased number of resting and terminally differen-
tiated NK cells correlated with several dosimetric para-
meters, and GI and GU toxicity. Table 5 summarizes
the Pearson’s correlations between the immune and
dosimetric variables on day 14 of RT, and 15-20 days
post-radiotherapy. Negative correlation throughout the
RT was detected between the NKT cell and T lympho-
cyte proportion and the volume of the rectum receiving
lower and higher doses, respectively. After completion
o fR Tt h eN Ka n dN K Tc e l l sw e r ef o u n dt ob em o r e
sensitive to higher doses. However, positive correlation
was found between differentiating B lymphocytes, and
the irradiated volume of rectum and bladder receiving
70 Gy.
The evaluation of GI and GU toxicity effects in the
WP (but not PO) group of patients revealed significant
up-regulation of T lymphocyte numbers (p = 0.047) and
NK cell effector function (p = 0.038) during radiother-
apy, as well as in patients developing acute GU toxicity.
Late GU toxicity-suffering patients had a significantly
increased number of CD8+ cytotoxic T cells, (p = 0.002)
and NK cell killing capability (Table 6). All statistically
significant correlation coefficients met the conditions of
required sample size. The GI and GU toxicity side
effects (after the completion of 3DCRT), but not
3DCRT itself, significantly decreased the distribution of
NKT cells in the WP group (Figure 4A). However, the
patients treated with the PO 3DCRT, suffering GI and
GU toxicities, had a lower number of NKT cells during
the entire follow-up (Figure 4B).
Discussion
In this study two different 3DCRT techniques (WP and
P O )w e r ea n a l y z e da n dt h ed e g r e eo fa s s o c i a t i o nw a s
determined between the occurrence and evolution of
acute and late GI and GU toxicities and the treatment
related characteristics in patients entering our hospital.
Important findings include: (i) a higher proportion of
acute GI toxicity in the WP 3DCRT technique group
and conversely a slightly higher proportion of late GI
and GU toxicity in the PO patient group; (ii) acute GI
toxicity as a significant predictor of late GI toxicity; (iii)
a strong dependence of the occurrence and evolution of
acute GI toxicity and of late GU toxicity on which
3DCRT technique is used; (iv) the association of both
acute and late GU toxicity and radical prostatectomy
performed prior to radiotherapy; (v) the influence of age
on both acute GI and GU toxicities; (vi) a correlation
between the percentage of volume of irradiated bone
marrow and a decreased number of leukocytes; and (vii)
the influence of radiotherapy preferentially on NK, NKT
and T cell subpopulations.
We found an increase of acute vs. pretreatment GI
symptoms predominantly in the WP group, even if the
patients were irradiated with lower doses compared with
the PO 3DCRT group. We assume that the limiting fac-
tor in high-volume irradiation is not the dosimetric
parameters, but the overall patient tolerance. In addi-
tion, the WP technique was undergone by patients with
advanced stages of disease, lower overall health status,
and suppressed immune functions. These observations
are supported by data of Jereczek-Fossa [19] and
Schultheiss et al. [20]; however, some investigators
didn’t demonstrate this correlation [21]. On the other
hand, the diminution of late GI and GU toxicities to
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Page 8 of 13grade 1 or to no toxicity in the majority of acute toxicity
(grade 1-3) suffering patients, was observed also in the
WP 3DCRT group.
Our data regarding the frequency of severe toxicities
are similar to those of other series, despite the fact that
a direct comparison of toxicities is difficult due to the
existence of many modified versions of the classification,
and modifications of grading scales. Similarities were
found between our results, the RTOG 9413 [22] analy-
sis, and the GETUG-01 [23] prospective study. The
diversity in the diagnostics could be created by indivi-
dual physicians due to the subjectivity of the scoring
system, when the same toxicity could be graded differ-
ently. Due to the findings of decreased late GI and GU
toxicities after 3DCRT in the cohort of our patients, we
compared these results with the studies using hypofrac-
tionated stereotactic body radiotherapy SBRT, which is a
new modality of localized prostate cancer RT. The
SBRT, together with innovations in image-guidance
technology, is able to automatically correct the move-
ment of the prostate during treatment, and deliver
highly-conformal beam profiles, which have greatly
enhanced the capability of delivering high dose fractions
to a well-defined target, with sharp dose fall-off towards
the bladder and rectum. Most of the studies concerning
SBRT as a monotherapy or even as a boost following
external beam radiotherapy presented only negligible
i n c i d e n c eo fs e v e r el a t eG Ia n dG Ut o x i c i t y .K a t ze ta l .
Table 4 Pearson’s correlation coefficients between bone marrow irradiation and immune parameters.
Dose
[Gy]
Volume [%] Number of leukocytes Proportion of NK cells
Median Range Correlation coefficient p Correlation coefficient p
5 44.54 30.31-98 -0.3177 0.140 0,5185 0,019
6 43.92 29.57-98 -0.3161 0.142 0,5197 0,019
7 43.38 28.95-98 -0.3161 0.142 0,5225 0,018
8 42.77 28.42-98 -0.3162 0.142 0,5239 0,018
9 42.31 27.95-97 -0.3170 0.141 0,5236 0,018
10 41.86 27.53-97 -0.3188 0.138 0,5224 0,018
11 41.34 27.12-97 -0.3213 0.135 0,5261 0,018
12 40.74 26.74-96 -0.3256 0.129 0,5196 0,019
13 40.13 26.36-96 -0.3314 0.122 0,516 0,020
14 39.63 26.00-96 -0.3361 0.117 0,5147 0,020
15 39.13 25.66-95 -0.3390 0.114 0,5133 0,021
16 38.66 25.34-95 -0.3402 0.112 0,5124 0,021
17 38.20 25.03-95 -0.3411 0.111 0,5117 0,021
18 37.77 24.72-94 -0.3423 0.110 0,5107 0,021
19 37.19 24.40-94 -0.3446 0.107 0,5096 0,022
20 36.35 24.05-94 -0.3463 0.105 0,5083 0,022
21 35.70 23.70-93 -0.3481 0.104 0,5065 0,023
22 35.20 23.33-93 -0.3496 0.102 0,5036 0,024
23 34.66 22.91-92 -0.3517 0.100 0,4984 0,025
24 34.13 22.37-91 -0.3675 0.084 0,4771 0,033
25 33.53 21.61-83 -0.3713 0.081 0,4579 0,042
44 10.97† 4.38-38.66 -0.4619 0.027 0,4270 0,060
45 9.97 4.22-35.05 -0.4645 0.026 0,3986 0,082
46 9.08 4.07-28.04 -0.4827 0.020 0,4153 0,069
47 8.39 3.93-23.31 -0.4769 0.021 0,3906 0,089
48 7.70 3.81-21.61 -0.4731 0.023 0,3935 0,086
49 7.07 3.50-20.48 -0.4701 0.024 0,4023 0,079
50 6.54 3.15-19.58 -0.4710 0.023 0,4130 0,070
51 6.00 2.83-18.84 -0.4751 0.022 0,4178 0,067
52 5.55 2.55-18.16 -0.4747 0.022 0,4187 0,066
53 5.21 2.30-17.50 -0.4709 0.023 0,4201 0,065
54 4.98 1.95-16.82 -0.4655 0.025 0,4208 0,065
The number of leukocytes and NK cell percentages were correlated to dose received and volume of irradiated bone marrow (n = 37)
*Required sample size for the obtained correlation coefficients (for a = 0.05 and power of the test b = 0.80) was calculated 32-34 patients
†Statistically significant results are marked in bold
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Page 9 of 13Table 5 Pearson’s correlation coefficients of immune cells proportions with dosimetric parameters
14
th date of 3D CRT 15-20 days after completion of 3D CRT
Variable vs. Variable Pearson’s
correlation
p Variable vs. Variable Pearson’s
correlation
p
T cells
(CD3+CD56-)
Dmin -0.5869 (20)* 0.012 NK cells
(CD3-CD56low)
Percentage of rectum
receiving 70 Gy
-0.5436 (23) 0.024
Dmean -0.5068 (27) 0.032
Dmax of rectum -0.4918 (29) 0.038
Dmax of urinary bladder -0.6089 (18) 0.007
Percentage of urinary bladder
receiving 70 Gy
-0.4906 (29) 0.007
NKT cells
(CD3+CD56+)
Dmin of rectum -0.5776 (20) 0.012 NKT cells
(CD3+CD56+)
Dmax of rectum -0.6755 (14) 0.000
Dmean of rectum -0.7243 (12) 0.001 Percentage of rectum
receiving 70 Gy
-0.4148 (42) 0.031
Percentage of rectum
receiving 40 Gy
-0.7363 (11) 0.000 Dmax of urinary bladder -0.6210 (17) 0.001
Percentage of rectum
receiving 50 Gy
-0.5613 (22) 0.015
NK cells
(CD3-D56low)
Dmin of rectum 0.3963 (47) 0.033 Activated B cells
(CD19+CD20+
CD38+)
Dmin of rectum 0.4582 (34) 0.016
Dmean of rectum 0.3724 (53) 0.047 Dmean of rectum 0.4342 (38) 0.024
Percentage of urinary bladder
receiving 70 Gy
0.5152 (26) 0.004 Percentage of rectum
receiving 50 Gy
0.4011 (46) 0.038
Percentage of rectum
receiving 60 Gy
0.5800 (20) 0.002
Terminally
differentiated NK
cells
(CD3-CD56+)
Dmin 0.4887 (30) 0.040 Terminally
differentiated
NK cells
(CD3-CD56+)
Dmax of rectum -0.5549 (22) 0.000
Percentage of rectum
receiving 70 Gy
0.4835 (30) 0.042 Dmax of urinary bladder -0.4608 (34) 0.016
Percentage of urinary bladder
receiving 70 Gy
0.5226 (26) 0.026
GI, GU toxicity 0.5166 (26) 0.028
*Required sample size for correlation coefficient for a = 0.05 and power of the test b = 0.80 is given in the brackets
Table 6 Influence of GI/GU toxicity on antitumor immune response.
Toxicity Variable Mean ± SD
(T)
Mean ± SD
(0)
p-value N
(T)
N
(0)
Acute GU
14
th day
of 3D-CRT
% of T cells
(CD3+D56-)
68.41 ± 0.70 58.33 ± 8.99 0.047 26 11 (6)*
Acute GU
14
th day
of 3D-CRT
Cytotoxicity 13.71 ± 5,21 6.54 ± 3.12 0.038 26 11 (6)
Late GU
15-20 days
after 3D-CRT
% of CTL
(CD3+CD8+)
15.99 ± 6.52 8.55 ± 2.26 0.002 13 24 (7)
Late GI
15-20 days
after 3D-CRT
Cytotoxicity 25.44 ± 4.96 13.82 ± 3.68 0.032 14 23 (2)
For comparison of immune parameters between the group of patients suffering from any acute and late GU or GI toxicity (T), and the group of patients without
toxicity side effects (0) after 3DCRT the t-test was applied.
*Required sample size in each group for given standard deviation and difference of means between groups for a = 0.05 and power of the test b = 0.80 is given
in the brackets
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Page 10 of 13[24,25], Freeman et al. [26] and other authors [27]
reported milder toxicity profiles in comparison with our
results, particularly in the case of late GI and GU
impairments. On the contrary, Jabbari et al. [28] pre-
sented in their study similar results as our ones in the
occurrence of severe late GU toxicity (grades 2-3), and
even worse outcomes in evolution of acute GU toxicity.
The analysis of GU toxicity is difficult, due to interfer-
ence with pre-existing dysfunction, age-related diseases,
and previous urological surgery [21,29]. We have to
remember that some of these pre-existing symptoms
could have been erroneously interpreted as acute or
even late GU toxicity. On the other hand, late bladder
damage can occur with a long latency time, potentially
resulting in the underestimation of the real severity of
late toxicity [30]. The difference in the time of clinical
manifestation could be the reason why some researchers
demonstrated the correlation of acute and late GI, but
n o tG Ut o x i c i t y[ 3 1 ] .T h e s eo u t c o m e sw e r ep r o v e di n
our study, as well.
The development of acute 3DCRT- induced GI and/or
GU damage was generally mild in both groups; and
none of the patients had an interruption of radiotherapy
due to toxicity side effects. The risk of both acute GI
and GU reactions depended preferentially on the age of
patients, in agreement with the results demonstrated by
Jereczek-Fossa et al. [31]. The biological variables and
different clinical decisions based on patient age could
participate on the final outcome. The association of
acute GU toxicity with the percentage of the urinary
bladder receiving 50 Gy found in our study was in
accordance with the results of Fiorino et al.[32] and
other authors [21,29], who reported a significant correla-
tion between DVH parameters and incontinence. Simi-
larly, the acute GI toxicity associates with the
percentage of rectum receiving 70 Gy as demonstrated
also by the Italian Association for Radiation Oncology
(AIRO) Group on Prostate Cancer (AIROPROS) 0101
trial (previous retrospective investigation [5], who
described that the dose of 70 Gy at rectum was predic-
tive for late G2-G3 bleeding), AIROPROS 0102 [33],
and by others [34,30,7,35]. Both late GI and GU toxici-
ties positively associated with the volume of the irra-
diated organ at risk, rectum and urinary bladder,
respectively. Furthermore, the late GI toxicity is asso-
ciated with stage T of TNM classification of the disease,
and is strongly influenced by acute GI toxicity. These
finding are in agreement with the published data of
Heemsbergen et al. [36]. The risk of late GU reactions
depended on the percentage of urinary bladder volume
receiving 40 Gy, the 3DCRT technique used, and the
previous urological surgery [21,29].
Originally, the primary mechanism of RT in cancer
reduction has been considered the neoplastic cell DNA
d a m a g e .H o w e v e r ,T a k e s h i m aet al. have found that
tumor-specific CTL, which were induced in the draining
lymph nodes and tumor tissue of mice by RT, are fun-
damental to the inhibition of cancer growth [37]. The
immunological evaluation performed during 3DCRT
showed a positive correlation of the number of activated
NK cells and the proportion of terminally differentiated
tumor targeted cytotoxic effectors with GI and GU toxi-
cities. Both of these subpopulations returned to normal
values or decreased after completing RT. In contrast, T
lymphocytes were decreased during RT and normalized
after its completion; while NKT cells were down-regu-
lated in all time periods. The acute GU and late GI and
GU toxicities significantly increased the T cell propor-
tion, NK cell-mediated cytotoxicity, and cytotoxic T cell
numbers. We assume that these changes are caused by
stress conditions induced by RT-damaged and GI or GU
toxicity-affected tissues, eliciting stimulation of cytotoxic
cells (NK and CTLs). These RT effects could be due to
inflammation following increased apoptotic/necrotic
events in the involved tissues. The surface expression or
extracellular release of stress proteins (e.g. MICs,
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Figure 4 Cumulative effect of radiation vs. toxicity on NKT cell
proportions in the course of 3DCRT. CD4+ out of CD3+CD56+
NKT cells were evaluated in the PBMC of patients suffering GI, GU
toxicities of grades 1-3 (T) or without any toxicity (0) undergoing
WP (n = 16; A) or PO (n = 21; B) types of radiotherapy. Pooled data
of patients in each treatment group, at all time points tested, are
presented as mean values, where standard deviation does not
exceed 10%.
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Page 11 of 13Hsp70), following tumor cell damage by RT, can play a
key role in immune system modulation [38]. These
molecules are ligands of the NK cell activation receptor
NKG2D [39], and can stimulate NK cell functional
maturation. Particularly, Hsp72 can act as an immunolo-
gical adjuvant [39,40], participating in the non-self
recognition of prostate cancer cells. Thus we can
hypothesize, according to results of Hurwitz et al.[ 1 2 ]
that the enhanced immune function, involving resting
and terminally differentiated NK cells during 3DCRT, as
well as the up-regulation of CTL number and the NK
cell-mediated cytotoxicity in GI or GU suffering
patients, could follow the release of HSPs either evoked
by radiation or by GI or GU toxicity-induced cellular
stress.
Conclusion
Our RT series included 197 patients who were treated
in one center and may serve as a basis for comparison
with other oncology centers, particularly in the Czech
R e p u b l i c .W ef o u n das t r o n gd e p e n d e n c eo ft h ed e v e l -
opment of GI and GU disorders on the 3DCRT techni-
que applied. Most important from a clinical point of
view and the overall quality of life of prostate cancer
patients after 3DCRT treatment was the diminution of
late GI and GU toxicity to grades 0-1 in a majority of
acute toxicities of patients suffering grades 1-3. The
relevance of our study lies in the complex evaluation of
clinical and radio-therapeutical variables describing the
correlations between OARs parameters, GI and GU
toxicity, phenotype, and the functional profile of
immune cells. Our results brought a new insight into
the 3DCRT impact on OARs and the antitumor
immune response.
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